Last Price$2.61Cboe Real-Time Last Sale as of 11:11AM ET 1/31/23
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Today's Change+0.06(2.16%)
Bid (Size)$2.60 (800)
Ask (Size)$2.61 (1,900)
Day Low / High$2.57 - 2.65
Volume503.5 K

Agenus Doses First Patient in Early Trial of AGEN1571 to Treat Solid Tumors

11:00AM ET 8/01/2022 MT Newswires
Agenus (AGEN) said Monday it has dosed the first patient in the phase 1 study of AGEN1571 to treat advanced solid tumors.

The trial will assess the safety, tolerability, pharmacokinetic and pharmacodynamic profiles of the drug, the company said.

Participants in the trial will be given AGEN1571 as a single agent or in combination with botensilimab and/or balstilimab.

The company said the launch of the study is based on preclinical data that showed the "superior potency and functional activity of AGEN1571 compared to the only known clinical-stage competitor and enhanced immune cell activation when combined with botensilimab or balstilimab."

Price: 2.57, Change: -0.01, Percent Change: -0.58